JD Sports Fashion was extending gains after impressing the market with its interim results yesterday, with pre-tax profits jumping by 26%. AstraZeneca was higher after announcing positive results from the TROPION-Breast01 phase three trial. On the downside was Halma, which dropped 4% as it continued to fall following an underwhelming first-half trading update yesterday. Analysts at Hargreaves Lansdown said there were supportive of Halma's business model and growth drivers. But its valuation is still ahead of the wider sector, adding: "There's plenty of pressure to deliver."